Multiple host and microbial targets

Multiple host and microbial targets is a categorical designation rather than a specific molecular entity, representing a therapeutic strategy that involves the simultaneous modulation of various biological pathways in both the human host and infecting or commensal microorganisms (Hopkins, 2008). This approach is characteristic of polypharmacological agents, such as nitazoxanide, which inhibits microbial enzymes like pyruvate:ferredoxin oxidoreductase while also activating host innate immune signaling (Rossignol, 2014). By acting on multiple fronts, these agents can provide broad-spectrum efficacy against bacteria, viruses, and parasites, often making them useful in treating complex or undiagnosed infections. However, because this designation covers a wide range of unrelated proteins and receptors across different species, it does not possess a singular biochemical definition or structural motif. The use of drugs hitting multiple host and microbial targets is particularly prevalent in gastrointestinal medicine, where agents like bismuth subsalicylate provide both antimicrobial activity and mucosal protection (Lambert, 1991). While effective, the lack of target specificity poses significant challenges for drug development, particularly regarding the risk of microbiome dysbiosis and unpredictable systemic off-target effects.

Other names

Multi-target therapyHost-microbe interactomeBroad-spectrum targetsHost-directed therapy

Simultaneous inhibition of essential microbial metabolic enzymes and modulation of host cellular signaling pathways, such as innate immune responses or mucosal protective factors.